ABBV vs EXEL

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Exelixis continues to demonstrate robust financial performance, driven by its flagship oncology drug, Cabometyx, which showed an 8.1% YoY increase in net product revenues. The company's Q1 2026 results exceeded EPS consensus and delivered strong YoY net income growth of 31.9%. A significant catalyst is the FDA's acceptance of the NDA for zanzalintinib (XL092) in metastatic colorectal cancer, with ...